Search results
Results from the WOW.Com Content Network
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The company also selectively out licenses limited use of its technology to other companies. Companies licensing ImmunoGen's technology include Amgen, Bayer HealthCare, Biotest, Genentech/Roche, Eli Lilly, Novartis, Sanofi, and Takeda. [9] Roche's Kadcyla (ado-trastuzumab emtansine) utilizes ImmunoGen's ADC technology. It has been approved and ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park . [ 1 ] In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra , a therapy against a rare form of cancer.
The company was founded in 2013 by Katherine A. High, Jeffrey Marrazzo, ... On February 23, 2022, Marrazzo named big-Pharma veteran Ron Philip as his successor. Mr ...
In 2017, the company scrapped a licensing deal for the drug with Seagen that led to the resignation of founder David M. Goldenberg. [7] Labetuzumab (IMMU-130) is an anti-CEACAM5-SN-38 antibody-drug conjugate in clinical trials for colorectal cancer. [citation needed] Veltuzumab is an anti-CD20 monoclonal antibody for treatment of cancer ...
Molecular Vaccines, Inc. was founded by Wayne T. Hockmeyer, David Mott, and Dr. James Young in 1988. [6] In 1989, Molecular Vaccines, Inc changed its name to MedImmune, Inc.
The Immune Response Corporation (IRC) was a pharmaceutical company that worked in the development of immunotherapeutic products. The firm was founded by Jonas Salk and Kevin Kimberlin when Kimberlin, "asked Salk to become lead scientific advisor for a new biotech company specializing in 'anti-idiotypes,' a novel vaccine technology."